Biologic efficacy in 147 pts w/ eosinophilic granulomatosis with polyangiitis - compares RTX (63), mepolizumab (51) or omalizumab (31). Remission/partial rates were better in RTX (49%/24%) and MEPO (78%, 10%) vs OMA (15%/33%) https://t.co/ZsCFVnasIJ